Cantor Fitzgerald Predicts FULC FY2025 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Fulcrum Therapeutics in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($1.21) for the year. Cantor Fitzgerald has a “Overweight” rating and a $10.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.50.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC opened at $6.88 on Friday. The firm’s 50 day simple moving average is $3.69 and its 200 day simple moving average is $3.80. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $10.13. The company has a market cap of $371.38 million, a PE ratio of -22.19 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 0.9% during the 1st quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company’s stock valued at $13,889,000 after acquiring an additional 42,985 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after acquiring an additional 2,155,675 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Fulcrum Therapeutics by 50.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock valued at $14,100,000 after acquiring an additional 1,000,000 shares during the period. Woodline Partners LP lifted its position in shares of Fulcrum Therapeutics by 110.3% during the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after acquiring an additional 739,713 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Fulcrum Therapeutics by 25.1% during the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company’s stock valued at $3,339,000 after acquiring an additional 142,578 shares during the period. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.